Revised Press Relase for the Quarter ended 31st December, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Microcap 250 and 3.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanjivani Paranteral Ltd reported a strong Q3FY26 with standalone revenue from operations rising 20.25% YoY to Rs. 208.63 mn, driven by 153.5% YoY growth in the Oral segment. Standalone EBITDA margin expanded to 18.62% (vs 16.5% in Q3FY25) and PAT grew 37.8% YoY to Rs. 26.16 mn. On the consolidated side, revenue grew 27.17% YoY to Rs. 220.6 mn and PAT rose 46.2% YoY to Rs. 27.76 mn, aided by the first-time contribution from the newly acquired SPL Infusion Pvt. Ltd., Pune facility. For 9MFY26, standalone revenue grew 4.5% YoY to Rs. 542.5 mn with PAT up 1.3% YoY at Rs. 59.8 mn, while consolidated revenue grew 6.81% YoY to Rs. 554.5 mn. Exports continue to dominate, accounting for about 77% of total revenue, mainly from CIS, Middle East, Africa, and Latin America markets.
Strong Q3 performance with healthy revenue growth, expanding margins, and the strategic Pune facility integration support a positive near-term outlook, though injectables segment softness and 9MFY26 being more modest may temper broader enthusiasm among retail shareholders.